A nanoparticle for use in the treatment of an ocular disease
AssigneeUniversitäT Regensburg
InventorsMARILENA BOHLEY, ACHIM GÖPFERICH
Life of this patent
Estimating the term…
Abstract
The present invention relates to a nanoparticle for use in the treatment of ocular diseases, in particular diseases of the retina (“retinopathies”) or of optic neuropathies, in particular glaucoma.
Claims21
1-15. (canceled)
A method of effectively preventing or treating, in a patient, one or several of an inflammatory component, an immune-response component, an angiogenic component and a neurodegenerative component of a retinal disease or of an optic neuropathy;
- wherein said method comprises administering a nanoparticle to a patient in need thereof;
- wherein said nanoparticle comprises:
- a core comprising a drug that has one or several of the following activities:
- anti-inflammatory activity, immune-suppressive activity, anti-angiogenic activity, neuroprotective activity, gene therapeutic activity and regulatory activity on gene expression;
- an amphiphilic shell surrounding said core, said amphiphilic shell comprising at least one phospholipid and, optionally, at least one surfactant;
- a targeting ligand binding to a receptor expressed on the surface of retinal pigment epithelial (RPE) cells and/or endothelial cells and/or optic nerve cells;
- said targeting ligand being covalently coupled to said amphiphilic shell.
The method according to claim i6, wherein said retinal disease is selected from retinal dystrophy and neovascular retinal diseases;
- and wherein said optic neuropathy is glaucoma.
The method according to claim i6, wherein said core comprises an oily or aqueous phase and said drug, said drug being dispersed in said oily or aqueous phase, said drug being dispersed in said oily or aqueous phase in the form of particles.
Dependencies are inferred from the claim text.